Second Opinions
and Individualized Cancer Treatment

Being diagnosed with cancer is one of the most difficult experiences a patient and their loved ones can face. It brings not only uncertainty and fear about the future but also the need to make complex decisions about diagnosis and treatment.

Modern oncology offers an expanding range of effective treatments. When cancer is diagnosed at an early stage, the goal is cure, often through surgery, radiation therapy, and systemic treatment. Even in more advanced stages, appropriately selected chemotherapy, endocrine therapy, immunotherapy, or molecularly targeted agents can offer a meaningful chance of cure or prolonged disease control.

Treating patients with metastatic cancer remains a particular challenge. Although cure is still not achievable in most cases, advances in cancer treatment have transformed the outlook for many patients. Cancers that only a decade or two ago were associated with rapid deterioration and limited survival can now, in selected circumstances, be controlled for years.

One of the most important goals of contemporary oncology is to transform advanced cancer, whenever possible, into a manageable chronic condition—allowing patients to live longer while maintaining the best possible quality of life.

However, no two cancers—and no two patients—are exactly alike. Tumors differ in their biology, aggressiveness, sensitivity to treatment, and mechanisms of resistance. Equally important are individual patient characteristics, including performance status, comorbidities, previous treatments, and personal preferences.

“We do not treat a cancer diagnosis alone—we treat an individual patient with a biologically unique disease.”

One of the greatest challenges in modern oncology is treating patients with advanced cancer whose disease continues to progress despite successive lines of systemic therapy.

As cancer evolves under the selective pressure of treatment, tumor cells undergo biological adaptation. Cells that survive successive therapies are often those capable of evading their effects through various resistance mechanisms. Consequently, heavily pretreated cancers may become increasingly heterogeneous and biologically complex, with multiple resistance mechanisms operating simultaneously.

In such circumstances, using yet another drug as monotherapy, targeting a single specific mechanism, may often prove insufficient. Even when an initial response is achieved, cancer cells may activate alternative survival pathways, adapt to therapeutic pressure, and eventually resume uncontrolled proliferation.

My approach to treating advanced, heavily pretreated cancers is based on the principle that, rather than targeting the disease through a single mechanism, we should—whenever clinically justified—attempt to interfere simultaneously with several complementary mechanisms essential to tumor survival and progression.

In practice, this involves developing individualized multidrug treatment strategies based not only on the histologic and molecular characteristics of the cancer but also on a detailed analysis of the patient’s entire treatment history. Particular attention is paid to which drugs were previously administered, the depth and duration of responses, the reasons for discontinuing each treatment, and the toxicities experienced.

A central component of this approach is the careful selection and optimization of drug doses, frequently using metronomic schedules. Metronomic chemotherapy generally involves the regular administration of cytotoxic agents at relatively low doses, often with minimal or no prolonged treatment-free intervals, rather than conventional intermittent chemotherapy given at higher doses. This strategy may make it possible to combine agents with different, potentially complementary mechanisms of action while seeking to maintain acceptable tolerability and limit treatment-related toxicity.

The objective is to make it increasingly difficult for cancer cells to evade treatment by simultaneously interfering with multiple processes involved in tumor proliferation, survival, adaptation, and resistance. Depending on the agents selected, these effects may also extend beyond malignant cells to the tumor microenvironment, including angiogenesis and other processes that support tumor growth.

“Rather than delivering a single powerful strike against one molecular target, I seek to apply sustained, multidirectional therapeutic pressure that limits the tumor’s ability to adapt and escape treatment.”

In essence, I aim to create a therapeutic environment in which cancer cells face several simultaneous obstacles to survival and proliferation, rather than allowing them to overcome one mechanism of action at a time.

Importantly, the objective is not always to eliminate every malignant cell or achieve the greatest possible reduction in tumor size. In advanced, heavily pretreated cancer, durable disease stabilization can itself represent a highly meaningful clinical benefit. If tumor proliferation can be sufficiently suppressed, disease control may be maintained for a prolonged period even without substantial tumor regression.

For this reason, I believe that, in selected clinical circumstances, achieving sustained disease control with acceptable tolerability may be more valuable than pursuing rapid but short-lived tumor regression through highly intensive, potentially toxic treatment.

This philosophy does not imply abandoning established standards of care, nor does it suggest that individualized multidrug metronomic regimens are universally superior to single-agent treatment. Rather, it reflects an individualized therapeutic approach that I consider in particularly challenging situations, following careful evaluation of the available scientific evidence, previous treatment outcomes, drug mechanisms of action, potential interactions, and risks of adverse effects.

Ultimately, my goal is not simply to maximize therapeutic pressure on cancer cells but to give patients the greatest possible opportunity to live longer with their disease under control while preserving independence, daily functioning, and quality of life.

Modern oncology relies on randomized clinical trials as the foundation of evidence-based treatment standards. However, the populations enrolled in these studies often differ substantially from patients encountered in the most advanced and clinically complex situations.

Heavily pretreated patients with multidrug-resistant cancers, rapidly progressive disease, impending visceral crisis, significant hepatic, renal, or bone marrow dysfunction, as well as frail older patients, are frequently excluded from randomized clinical trials. Some may be eligible for early-phase studies, which primarily focus on establishing the safety, tolerability, and appropriate dosing of investigational agents rather than comparing alternative salvage treatment strategies.

Consequently, generating high-quality evidence to guide treatment decisions in these populations is exceptionally difficult. Moreover, the likelihood of conducting large randomized trials evaluating individualized multidrug metronomic regimens in such heterogeneous, heavily pretreated populations remains limited.

This does not mean that an absence of evidence should be interpreted as evidence of efficacy. Rather, when standard treatment options have been exhausted, therapeutic decisions may have to rely on less comprehensive clinical evidence, an understanding of cancer biology, previous treatment outcomes, drug mechanisms of action, and an individualized assessment of potential benefits and risks.

In these circumstances, clinical experience, rational treatment design, and continuous adaptation of therapy according to efficacy and tolerability become particularly important.

A particularly important area of my clinical practice involves patients with advanced malignancies whose established treatment options are limited or exhausted, whose cancers have progressed despite multiple prior regimens, or whose clinical condition makes further anticancer therapy especially challenging.

In these situations, every treatment decision should begin with a comprehensive reassessment of the disease and the patient’s previous treatment course. This includes tumor biology, prior therapies, the nature and duration of earlier responses, potential mechanisms of resistance, treatment-related toxicities, and current functional status.

Modern oncology offers many therapeutic tools. However, using them optimally sometimes requires moving beyond rigid, algorithm-driven treatment decisions and considering the individual biological and clinical context. This does not mean disregarding evidence-based standards. On the contrary, a thorough understanding of established guidelines, clinical trial results, and the pharmacology of anticancer agents provides the foundation for responsible therapeutic individualization.

I pay particular attention to patients who have previously been considered ineligible for further anticancer therapy. Such a decision does not necessarily mean that every potentially meaningful treatment option has been exhausted. In selected cases, a detailed reassessment may identify alternative approaches that were not previously considered or were thought to be unsuitable. At the same time, further anticancer treatment is not always beneficial or appropriate. Sometimes the most responsible course is to focus on symptom management, supportive care, and quality of life.

What matters most is that neither the decision to pursue additional treatment nor the decision to forgo it should be made automatically, without carefully considering the individual patient’s circumstances.

I regard a second medical opinion as an important part of modern, patient-centered cancer care.

For many cancers diagnosed at an early stage, internationally accepted guidelines offer well-established treatment pathways. Following these recommendations generally provides the best prospect of successful treatment. Nevertheless, questions may arise about the diagnosis, sequencing of therapies, or optimal extent of treatment.

A second opinion may be particularly valuable in advanced cancer, especially after multiple lines of treatment have failed. Therapeutic choices may then be less clearly defined and depend on disease biology, prior treatment outcomes, comorbidities, functional status, and patient preferences. Oncologists with different areas of expertise and clinical experience may identify different but medically reasonable approaches.

Seeking a second opinion should not be interpreted as a lack of trust in the treating physician. Instead, it can strengthen decision-making by ensuring that the diagnosis has been carefully reviewed and relevant diagnostic and treatment options have been considered.

I frequently encourage my own patients to seek additional opinions from other oncologists, particularly those with expertise in the specific cancer involved. In my experience, an independent assessment of a complex case can reveal possibilities, uncertainties, or clinical considerations that may not previously have received sufficient attention.

A second opinion does not necessarily lead to a change in treatment. Often, its greatest value is confirming that the current approach is appropriate and helping the patient continue treatment with greater confidence.

I firmly believe that exchanging clinical experience, remaining open to alternative perspectives, and being willing to revisit earlier decisions are essential to responsible oncology practice.

I believe that effective cancer care must be built on a genuine partnership between physician and patient.

An oncologist’s responsibility extends beyond recommending treatment. It includes explaining the goals of therapy, the realistic likelihood of benefit, the risks of adverse effects, and the potential impact on everyday life.

Patients should understand not only which treatment is being proposed but also why it is recommended, what alternatives exist, and how the different choices may affect their future. This allows them to participate meaningfully in decisions about their care.

In advanced cancer, finding the right balance between treatment intensity, the likelihood of clinical benefit, and preservation of quality of life is particularly important.

The most intensive treatment is not necessarily the most appropriate. In some circumstances, modifying treatment schedules, adjusting doses, or choosing a different strategy may allow treatment to continue longer, improve tolerability, and preserve daily functioning.

“Success in cancer care is not measured solely by tumor response or prolonged survival, but also by the preservation of quality of life, independence, and the patient’s sense of control over their own future.”